Abstract: A wide bandwidth continuous-time sigma-delta ADC, operating between 20 and 40 MS/s output data rate, is implemented in 130-nm CMOS. The circuit is targeted for applications that demand high ...

Abstract: This paper presents a low-power 12-bit 100-MS/s asynchronous successive approximation register analog-to-digital converter (SAR ADC). Several techniques are developed to enhance the ADC ...

If you want to become a professional embedded developer, you should be able to effectively use industry-standard APIs and SDKs provided and approved by microcontroller vendors, such as CMSIS for ARM ...

What makes this candidate ideal is that it is an antibody-drug conjugate [ADC] that targets DLL3-expressing solid tumors. Two Catalysts In 2025 For ADC Candidate Could Launch Another Solid Program ...

"MHB088C has demonstrated robust efficacy with great safety profiles, with no major hematological toxicity or ILD, positioning the program as a best-in-class B7-H3 ADC," Cao added. "With Qilu's ...

ADRX-0706 is a Nectin-4-targeted antibody-drug conjugate (ADC). The agent is being evaluated in a phase 1a/b clinical trial (NCT06036121) for the treatment of advanced solid tumors. The FDA has ...

“We are excited to advance IDE849, a potential first-in-class DLL3 TOP1 ADC, into a Phase 1 study in the U.S. DLL3 is upregulated in multiple solid tumor types, including small cell lung cancer (SCLC) ...

By integrating terminal functionality into the IDE, Junie enhances overall efficiency and reduces the cognitive load associated with managing multiple tools. A defining characteristic of Junie is ...

Designed to tackle the most pressing challenges in modern software development, this next-generation IDE and AI assistant promises to transform how teams collaborate and innovate. From streamlined ...

5. CS2011 exhibited a pharmacokinetic (PK) profile comparable to those of monoclonal antibodies in rodents. CS5007 is a bispecific ADC targeting both EGFR and HER3, developed with CStone's proprietary ...

SOUTH SAN FRANCISCO, Calif., May 6, 2025 /PRNewswire/ -- IDEAYA Biosciences, Inc. (NASDAQ: IDYA), a precision medicine oncology company committed to the discovery and development of targeted ...

Targeting to evaluate IDE849 (SHR-4849) in SCLC, NETs, and other DLL3-upregulated solid tumors, and in combination with IDE161/PARG to potentially enhance durability Targeting to present clinical ...